The Challenge of Time-to-Event Analysis for Multiple Events: A Guided Tour From Time-to-First-Event to Recurrent Time-to-Event Analysis. [PDF]
Biom JSchmeller S +4 more
europepmc +1 more source
Letter to the Editor Regarding: "Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain". [PDF]
Oncol Thervan Nimwegen KJM +3 more
europepmc +1 more source
Statistical inferences on summary measures of interval censored data in cancer clinical trials
Statistical inferences on summary measures of interval censored data in cancer clinical trials2019
openaire
A Response to: Letter to the Editor Regarding "Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain". [PDF]
Oncol TherLozano V +6 more
europepmc +1 more source
On Window Mean Survival Time With Interval-Censored Data. [PDF]
Stat MedIijima T, Momozaki T, Ando S.
europepmc +1 more source
An Alternative Treatment Effect Measure for Time-to-Event Oncology Randomized Trials. [PDF]
Cancers (Basel)Hutson AD, Yu H.
europepmc +1 more source
ESMO-MCBS v2.0: Advances, challenges, and perspectives in the assessment of clinical benefit in oncology. [PDF]
JHEP RepMauro E, Serra-Burriel M.
europepmc +1 more source
Identifying and avoiding design related biases in observational studies using the target trial framework. [PDF]
BMJ MedHansford HJ +4 more
europepmc +1 more source
Adjusting for truncated study duration in recurrent event analysis: A weighting approach for clinical trials. [PDF]
PLoS OneMichael Raj A J, Thomas T, Dwarkanath P.
europepmc +1 more source